Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny O'Nions

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Future Oncology (London, England)|September 21, 2019
The role of obinutuzumab in the management of follicular lymphomaJenny O'Nions, William Townsend
Oncogene|October 17, 2003
Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2Jenny O'Nions, Martin J Allday
The Journal of General Virology|March 25, 2004
Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell-derived mitogensJenny O'Nions, Martin J Allday
BMJ Case Reports|August 6, 2013
A complex neurological presentation of syphilisMax Kamath, Maleeha Rizvi, Jenny O'Nions, et al.
The Journal of General Virology|April 16, 2005
Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cellsRobert Touitou, Jenny O'Nions, Judith Heaney, et al.
Journal of Virology|September 22, 2006
Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53Jenny O'Nions, Abigail Turner, Richard Craig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopausePhilip Savage, Rosie Cooke, Jenny O'Nions, et al.
Blood|September 15, 2005
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignanciesNelofer Syed, Paul Smith, Alexandra Sullivan, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
Current Research in Translational Medicine|January 23, 2024
Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'Dipal Mehta, Samah Alimam, Donal P McLornan, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Future Oncology (London, England)|September 21, 2019
The role of obinutuzumab in the management of follicular lymphomaJenny O'Nions, William Townsend
Oncogene|October 17, 2003
Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2Jenny O'Nions, Martin J Allday
The Journal of General Virology|March 25, 2004
Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell-derived mitogensJenny O'Nions, Martin J Allday
BMJ Case Reports|August 6, 2013
A complex neurological presentation of syphilisMax Kamath, Maleeha Rizvi, Jenny O'Nions, et al.
The Journal of General Virology|April 16, 2005
Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cellsRobert Touitou, Jenny O'Nions, Judith Heaney, et al.
Journal of Virology|September 22, 2006
Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53Jenny O'Nions, Abigail Turner, Richard Craig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopausePhilip Savage, Rosie Cooke, Jenny O'Nions, et al.
Blood|September 15, 2005
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignanciesNelofer Syed, Paul Smith, Alexandra Sullivan, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
Current Research in Translational Medicine|January 23, 2024
Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'Dipal Mehta, Samah Alimam, Donal P McLornan, et al.
Pageof 3